Skip to main content
Sernova Biotherapeutics Inc. logo

Sernova Biotherapeutics Inc. — Investor Relations & Filings

Ticker · SVA ISIN · CA81752F1062 TSX Professional, scientific and technical activities
Open in API
Filings indexed 277 across all filing types
Latest filing 2026-05-07 Regulatory Filings
Country CA Canada
Listing TSX SVA

About Sernova Biotherapeutics Inc.

https://sernova.com/

Sernova Biotherapeutics Inc. is a clinical-stage biotechnology company developing regenerative medicine therapeutics aimed at correcting the underlying cause of chronic diseases, such as Type 1 Diabetes (T1D). The company's core technology is the proprietary Cell Pouch™ bio-hybrid organ platform. This platform is engineered to merge the Cell Pouch device with therapeutic cells, including blood-derived stem cells, to create a functional bio-hybrid organ. The objective of this therapeutic solution is to restore the body's normal function by correcting deficiencies in hormones and proteins, providing a durable treatment option for patients with chronic conditions.

Recent filings

Filing Released Lang Actions
Report of exempt distribution (45-106F1).pdf
Regulatory Filings
2026-05-07 English
Report of exempt distribution (45-106F1).pdf
Share Issue/Capital Change Classification · 1% confidence The document is a Canadian securities regulatory Form 45-106F1 (“Report of Exempt Distribution”). It provides detailed information on a private placement of common shares and warrants, including distribution dates, share counts, prices, purchaser jurisdictions, and total proceeds. This is not an earnings release, annual report, or management commentary but a formal notification of a share issuance under NI 45-106. Therefore it falls under the “Share Issue/Capital Change” category (Code: SHA).
2026-04-25 English
News release - English.pdf
Transaction in Own Shares Classification · 1% confidence The document is a detailed announcement of the company’s share buyback program, listing dates, number of shares repurchased, prices, amounts, cumulative totals, and the impact on treasury shares and share capital. This fits the definition of "Transaction in Own Shares" (POS), which covers share repurchase reports. It is not a general financing update, director trade report, or regulatory notice. Hence, the appropriate classification is POS.
2026-04-23 English
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a corporate press release announcing the closing of various financing transactions (convertible debentures, unit financing, debt settlements for units of capital). It provides details on amounts raised, parties involved, and statutory hold periods. This aligns with category 6: Capital/Financing Update (CAP), as it updates investors on the company’s fundraising and capital structure changes.
2026-04-23 English
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a press release announcing the closing of recently approved financing transactions, including convertible debentures, unit financings, and debt settlements—updates on company fundraising and capital structure changes. This matches the Capital/Financing Update category.
2026-04-23 English
Report of exempt distribution (45-106F1).pdf
Regulatory Filings Classification · 1% confidence The document is a Canadian securities regulatory compliance form (Form 45-106F1 Report of Exempt Distribution) detailing the issuer’s exempt distribution under National Instrument 45-106, filed to SEDAR+. It is not an annual or interim report, earnings release, or investor presentation, but a mandatory regulatory filing. This falls under the general “Regulatory Filings” category (RNS) for miscellaneous compliance filings that do not fit the other specific classes.
2026-04-22 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.